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Abstract
Background. Glioma prognosis depends on isocitrate dehydrogenase (IDH) mutation status. We aimed to predict 
the IDH status of gliomas from preoperative MR images using a fully automated hybrid approach with convolu-
tional neural networks (CNNs) and radiomics.
Methods. We reviewed 1166 preoperative MR images of gliomas (grades II–IV) from Severance Hospital (n = 856), 
Seoul National University Hospital (SNUH; n = 107), and The Cancer Imaging Archive (TCIA; n = 203). The Severance 
set was subdivided into the development (n = 727) and internal test (n = 129) sets. Based on T1 postcontrast, T2, 
and fluid-attenuated inversion recovery images, a fully automated model was developed that comprised a CNN 
for tumor segmentation (Model 1) and CNN-based classifier for IDH status prediction (Model 2) that uses a hybrid 
approach based on 2D tumor images and radiomic features from 3D tumor shape and loci guided by Model 1. The 
trained model was tested on internal (a subset of the Severance set) and external (SNUH and TCIA) test sets.
Results. The CNN for tumor segmentation (Model 1) achieved a dice coefficient of 0.86–0.92 across datasets. Our 
hybrid model achieved accuracies of 93.8%, 87.9%, and 78.8%, with areas under the receiver operating character-
istic curves of 0.96, 0.94, and 0.86 and areas under the precision-recall curves of 0.88, 0.82, and 0.81 in the internal 
test, SNUH, and TCIA sets, respectively.
Conclusions. Our fully automated hybrid model demonstrated the potential to be a highly reproducible and gener-
alizable tool across different datasets for the noninvasive prediction of the IDH status of gliomas.
Key Points
1.  Prognosis of gliomas depends on IDH mutation status.
2.  Our hybrid model is based on convolutional neural networks that integrate shape and 
loci radiomics.
3.  This fully automated hybrid model can predict IDH status across 3 datasets.
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Glioma is the most common malignant primary brain 
tumor in adults.1 Gliomas have a wide range of prog-
noses depending on the World Health Organization (WHO) 
grade, with a median survival of 14 months for glioblast-
omas (grade IV)2 and of more than 7 years for lower grade 
gliomas (grades II and III).3 Recently, molecular subtypes, 
such as isocitrate dehydrogenase (IDH) mutation status, 
have been reported as important factors for the tumor be-
havior of gliomas.4 Specifically, lower grade gliomas with 
wildtype IDH were reported to be similar to glioblastomas 
in terms of molecular profile and prognosis, while IDH mu-
tated glioblastomas showed a better prognosis than IDH 
wildtype glioblastomas.5,6 Moreover, anaplastic gliomas 
(grade III) with wildtype IDH have a worse prognosis than 
glioblastomas with an IDH mutation (grade IV).7 As such, 
IDH status has been integrated into the 2016 WHO clas-
sification scheme for gliomas.8 Additionally, the effect 
of gross total tumor resection on the prognosis of lower 
grade gliomas was reported to depend on the IDH mutation 
status.9 Therefore, the preoperative prediction of IDH status 
is necessary for appropriate treatment planning.
Deep convolutional neural networks (CNNs) are a rep-
resentative method to exploit high-dimensional numeric 
information from images by learning relevant features 
directly from image signal intensities. CNNs have diag-
nostic value for predicting the IDH status of gliomas.10–13 
However, there are several hurdles for clinical imple-
mentation of CNNs for IDH status prediction; if the model 
prediction process is not fully automated, any operator-
dependent process such as manual segmentation can be 
time-consuming, which limits clinical feasibility and is a 
source of interrater variability. Moreover, image signal 
intensity–based CNNs are unable to directly incorporate 
information from 3D tumor shapes and locations that are 
associated with IDH status.10,11 Additionally, since image 
signal intensities are likely to be sensitive to different 
MRI protocols and machines and because they may affect 
the performance of CNN models, external testing is nec-
essary to confirm model generalizability across different 
institutions. Although previous studies have applied 
CNNs to brain MR images for the prediction of molecular 
profiles of gliomas,10–12,14 many studies lacked external 
testing for confirming model generalizability.10,14 To mit-
igate these limitations, in this study, model testing for 
generalizability was conducted on 3 datasets, including 2 
external test sets, after model training on a dataset from 
one institution.
The aim of this study was to predict the IDH status of 
patients with gliomas (grades II-IV) from preoperative MR 
images using a fully automated hybrid approach that inte-
grates the following: (i) a CNN for automated tumor seg-
mentation and (ii) a CNN-based classifier for IDH status 
prediction that incorporated both 2D images and the 
radiomic features of 3D tumor shape and loci.
Materials and Methods
This retrospective study was approved by the institutional 
review board of Severance Hospital, Seoul, South Korea. 
The requirement for informed consent was waived.
Patients
The patient enrollment process is shown in Fig. 1. A total of 
1202 patients who underwent preoperative MRI for newly 
diagnosed gliomas (grades II–IV) from January 2006 to 
June 2019 at Severance Hospital were considered for in-
clusion. The inclusion criteria were as follows: (i) patholog-
ically confirmed glioma, (ii) known IDH mutation status, 
(iii) preoperative MRI inclusive of postcontrast T1-weighted 
(T1C), T2-weighted (T2), and fluid-attenuated inversion 
recovery (FLAIR) images, and (iv) age ≥18 years. The ex-
clusion criteria were as follows: (i) history of biopsy or sur-
gery for brain tumor (n = 182), (ii) the absence of T1C, T2, 
or FLAIR images (n = 83), and/or (iii) unknown IDH status 
(n  =  81). Therefore, a total of 856 patients were enrolled 
from Severance Hospital (Severance set). These patients 
were semi-randomly allocated into development (n = 727) 
and internal test sets (n = 129), with stratification for IDH 
status. The development set was subsequently divided into 
the training (n = 596) and tuning (n = 131) sets. For external 
testing, a total of 107 consecutive patients from January 
2017 to January 2018 from the Seoul National University 
Hospital (SNUH set)15 and 203 patients from The Cancer 
Imaging Archive (TCIA set)16 were enrolled in accordance 
with the same criteria. The list of enrolled patients from the 
set from TCIA is shown in eTable 1. The details of IDH status 
evaluation are provided in eDocument 1.
Importance of the Study
CNNs and radiomics have shown potential to be used 
for the noninvasive assessment of IDH mutation status. 
Herein, based on conventional MR images from 1166 
patients with gliomas, we developed a fully automated 
hybrid model based on a CNN that integrates 2-dimen-
sional tumor signal intensity and radiomic features 
from 3D tumor shape and loci. We tested the model on 
3 datasets, achieving accuracies of 78.8%–93.8% and 
areas under the receiver operating characteristics 
curves of 0.86–0.96. Our results (i) show that the hy-
brid approach allows for the accurate prediction of 
IDH status; (ii) demonstrate the potential to use this 
automated process as a highly reproducible and gen-
eralizable method for noninvasive characterization 
of gliomas; and (iii) implicate the clinical considera-
tion regarding the similarity between training and test 
data that is required for ideal generalizability of model 
performance.
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Study Design
The study design is summarized in Fig. 2. Our automated 
hybrid model comprised 2 deep CNN models (Models 
1 and 2)  and a fully automated pipeline between the 2 
models. A CNN for automatic tumor segmentation (Model 
1)  was trained to yield tumor masks based on T1C and 
FLAIR images, and a CNN-based binary classifier for IDH 
status (Model 2)  was trained to predict the IDH status 
based on (i) the image inputs of T1C and T2 images and 
tumor masks from Model 1, (ii) the numeric inputs con-
sisting of radiomic features from the tumor shape and loci 
extracted from the tumor masks of Model 1, and (iii) age. 
Model 1 and Model 2 constituted the hybrid model using 
the fully automated pipeline between the two models. The 
CNN models were developed based on the Severance de-
velopment set and tested on 1 internal test set (a subset 
of the Severance set) and 2 external test sets (SNUH and 
TCIA sets).
Image Acquisition and Processing
The details of the image acquisition parameters are 
summarized in eFigure 1 and eTable 2. The most com-
monly used imaging parameters and their proportions 
in each dataset are as follows; magnetic field strength: 
3 T in the Severance (98.2%) and SNUH (85.0%) sets and 
1.5 T in the set from TCIA (55.7%); manufacturer: Philips 
in the Severance set (98.1%), Siemens in the SNUH set 
(79.4%), and General Electric in the set from TCIA (73.4%); 
T1C slice thickness: ≤1.0 mm in the Severance (83.1%) and 
SNUH (100.0%) sets and 2.0–3.0 mm in the set from TCIA 
(36.5%); T2 slice thickness: 6.0–7.0 mm in the Severance 
(45.9%) and SNUH (50.5%) sets and 4.0–5.0  mm in the 
set from TCIA (32.5%); FLAIR slice thickness: 6.0–7.0 mm 
in the Severance (54.2%) and SNUH (88.8%) sets and 
2.0–3.0  mm in the set from TCIA (42.4%). The detailed 
image processing methods are described in eDocument 
2. Briefly, T1C, T2, and FLAIR images were registered to 
an identical 1-mm isovoxel spatial coordinate. The im-
ages were subjected to signal intensity normalization 
and resampling to sizes of 128 × 128 × 128. The ground-
truth whole tumor was defined as high-signal intensity on 
FLAIR images and was segmented by a neuroradiologist 
and confirmed by another neuroradiologist (S.B.  and 
Y.S.C., with 4 and 7 years of experience in neuroradiology, 
respectively).
CNN for Tumor Segmentation (Model 1)
For the CNN for tumor segmentation, the modified 3D 
U-shaped CNN architecture proposed by Kickingereder and 
Isensee et al17 was revised to use T1C and FLAIR images 
with sizes of 128 × 128 × 128 as network inputs and yield 
whole tumor segmentation only. The details of the archi-
tecture and training process are described in eDocument 3.
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Fig. 1 Flow diagram of the study population.
  








CNN Classifier for IDH Status Prediction 
(Model 2)
The Model 2 architecture is shown in Fig. 2. Briefly, our 
CNN classifier for IDH status prediction was derived 
from the well-known 34-layer ResNet architecture18 
(hereinafter referred as the conventional ResNet) shown 
in eFigure 2 that contains the initial 7 × 7 convolution and 
layers 1–4 comprising 3, 4, 6, and 3 residual blocks with 
each residual block having the 3 × 3 convolution twice. 
For the hybrid approach, additional fully connected 
layers were added to the conventional ResNet to build 
Model 2, which used the additional numeric inputs along 
with the image inputs.
The Model 2 image input comprised axial T1C and T2 im-
ages and tumor masks of 128 × 128 size. To extract compre-
hensive 2D signal intensity information from the tumor, the 
axial slice with the maximum tumor area was automatically 
selected as the “maximum tumor image,” and the other 4 
images were extracted from 4 upper (+4), 2 upper (+2), 2 
lower (−2), and 4 lower (−4) slices from the maximum tumor 
images. Thus, 5 axial slices per patient were automatically 
selected based on tumor segmentation and were considered 
as individual samples in model development and testing. 
The Model 2 numeric inputs were selected among a total 
of 24 features consisting of age and shape- and loci-based 
radiomic features (eDocument 4) that were automatically 
extracted from the tumor masks, according to the univariate 
t-test in terms of IDH status in the development set.
The details of the Model 2 training process are described 
in eDocument 5. Briefly, the conventional ResNet was first 
trained using the image inputs as a “warm-up training.” 
Then, the pretrained weights from the layers that were 
close to image inputs were imported to Model 2 and fixed, 
and the rest of the layers of Model 2 were fine-tuned using 
both image and numeric inputs.
Fully Automated Pipeline and Hybrid Model
Our automated hybrid model was built by connecting 
Model 1 for segmentation with Model 2 for IDH status pre-
diction using the fully automated pipeline. Our trained au-
tomated hybrid model was tested in 1 internal test set (a 
subset of the Severance set) and 2 external test sets (the 
SNUH and TCIA sets). The internal test set, as well as the 
SNUH and TCIA sets, were separated and not revealed 
during model development. The first step of automated 
hybrid model testing was to obtain automatic tumor seg-
mentation of the test samples from Model 1. These seg-
mentations were subsequently used for the selection of 
the 2D image inputs (5 axial slices) of Model 2 and the 
extraction of 3D shape- and loci-based radiomic features 
that were used along with age as the numeric inputs of 
Model 2.  All processes were automated, and the trained 
models and code for image processing are available at 
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Fig. 2 Fully automated hybrid model for IDH status prediction. In Model 2, layers 1–4 consisted of 3, 4, 6, and 3 residual blocks, with each block 
containing the 3 × 3 convolutions twice.
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Model Explanation
To understand which part of the image inputs are rele-
vant for IDH status prediction, ablation analysis was con-
ducted19 and saliency maps were generated, which were 
assessed by 2 neuroradiologists (S.B. and J.K.) based on 
a survey,20 as described in eDocument 6. The variable im-
portance of numeric inputs was calculated based on the 
shape/loci radiomics classifier that is mentioned later, 
using the “varImp” function of “caret” R package.
Statistical Analysis
The performance of Model 1 for tumor segmentation was 
measured using the dice similarity coefficient that meas-
ures the extent of spatial overlap between 2 binary seg-
mentation masks (ie, ground-truth segmentation from 
radiologists and automatic segmentation from Model 
1)  and ranges from 0 (no overlap) to 1 (perfect agree-
ment).21 The diagnostic performance of the automated 
hybrid model that connected Models 1 and 2 was meas-
ured in terms of accuracy, area under the receiver oper-
ating characteristic curve (AUROC), and area under the 
precision-recall curve (AUPRC), using the “PRROC” R 
package. The 95% confidence intervals (CIs) of the AUROC 
and AUPRC values were calculated from 2000 iterations 
of bootstrapping with the predicted probabilities from the 
models. The probability threshold for the accuracy calcu-
lation was set to 0.5; thus, a predicted probability of ≥0.5 
was classified as an IDH mutation, and other values were 
classified as IDH wildtype. The diagnostic accuracy of the 
automated hybrid model was measured for both individual 
samples and the mean probability from 5 samples per 
patient. Beside the automated hybrid model and the con-
ventional ResNet, to assess the diagnostic value of the nu-
meric features, the shape/loci radiomics classifier was built 
based on the numeric inputs of Model 2 using the random 
forest algorithm and 10-fold cross-validation within the de-
velopment set using the “caret” R package.22 Additionally, 
the diagnostic model that used age alone was built using 
logistic regression on the development set. The diagnostic 
performance on the test sets was measured for the conven-
tional ResNet with image inputs, the shape/loci radiomics 
classifier with numeric inputs, and the prediction using age 
alone. To evaluate whether the image-integrated model (ie, 
the automated hybrid model) predicts IDH status more ac-
curately than clinical factors alone (ie, age), accuracy and 
AUROCs were compared via an exact binomial test (with 
the “binom.test” R function) and a method described by 
Delong et al.23 A P-value of <0.05 was considered to indi-
cate a statistically significant difference. All statistical ana-
lyses were conducted using the R software, v3.4.4.
Results
Characteristics of the Study Population
The clinical characteristics of a total of 1166 patients from 
the Severance Hospital, TCIA, and SNUH are summarized 
in Table 1. In terms of IDH status, the SNUH set showed no 
difference compared with the Severance set (P  >  0.999), 
whereas the set from TCIA had a significantly higher prev-
alence of IDH mutation than the Severance set (P < 0.001). 
In terms of WHO grade, the SNUH set had a significantly 
higher proportion of grade II gliomas (P = 0.005) and the 
set from TCIA showed a nonsignificant tendency toward a 
higher proportion of lower grade gliomas (P = 0.054) than 
the Severance set. No significant difference was found 
in terms of age (P  =  0.194 for the Severance vs SNUH 
sets; and P = 0.818 for the Severance vs TCIA sets) or sex 
(P = 0.721 for the Severance vs SNUH sets; and P = 0.305 
for the Severance vs TCIA sets).
Model Performance
Model 1 (CNN for tumor segmentation) was achieved 
through 46 epochs of training and yielded dice coefficients 
of 0.91 ± 0.04, 0.92 ± 0.01, and 0.86 ± 0.08 in the internal 
test, SNUH, and TCIA sets, respectively. The pretrained con-
ventional ResNet with image inputs was achieved through 
111 epochs of training. Among the 24 numeric features of 
shape and loci features and age, 20 features showed signif-
icant differences according to IDH status and were used as 
the numeric inputs of Model 2. After a part of the weights 
were imported from the pretrained conventional ResNet, 
Model 2 was achieved through 72 epochs of fine-tuning. The 
performance of the automated hybrid model on test sets is 
summarized in Table 2 and Fig. 3. With the mean probabil-
ities from 5 samples per patient, our model achieved ac-
curacies of 93.8%, 87.9%, and 78.8%, with AUROCs of 0.96 
(95% CI: 0.93–0.99), 0.94 (95% CI: 0.89–0.97), and 0.86 (95% 
CI: 0.80–0.91) and AUPRCs of 0.88 (95% CI: 0.72–0.98), 0.82 
(95% CI: 0.65–0.94), and 0.81 (95% CI: 0.71–0.88) in the in-
ternal test, SNUH, and TCIA sets, respectively.
The performances of the conventional ResNet, shape/
loci radiomics classifier, and the prediction using age 
alone are summarized in Table  3. The conventional 
ResNet, shape/loci radiomics classifier, and prediction 
using age alone achieved accuracies of 73.5%–92.2%, 
75.4%–85.3%, and 68.5%–72.1%; AUROCs of 0.81–0.95, 
0.84–0.90, and 0.74–0.81; and AUPRCs of 0.74–0.87, 0.65–
0.85, and 0.44–0.68, respectively, in the test sets. The au-
tomated hybrid model was superior to prediction using 
age alone across all datasets (all P  <  0.05 for accuracy 
and AUROC, eTable 3).
Model Explanation
The ablation analysis results are shown in eTable 4. 
Compared with the performance of the original conven-
tional ResNet, in the ablation analysis with a decreased 
number of axial images per patient, decreased number of 
image sequences, or masking of the nontumor brain tissue 
area, we observed decreased diagnostic performance, 
with the accuracy, AUROC, and AUPRC in the ranges 
of 67.8%–86.8%, 0.71–0.93, and 0.62–0.84, respectively. 
When the tumor area was masked from image inputs, the 
lowest diagnostic performance was yielded with accur-
acies of 58.4%–72.1%, AUROCs of 0.55–0.71, and AUPRCs 
of 0.37–0.47.








The saliency map survey results and representative 
cases are shown in eTable 5 and eFigure 3. On the T1C sali-
ency maps, the main activation areas were the enhancing 
tumor areas if the tumor had enhancing portions and the 
tumor periphery along the margin, regardless of the pres-
ence of enhancement. On T2 saliency maps, the main ac-
tivation area involved the entire tumor area. Additionally, 
outside the tumors, the peritumoral area along the tumor 
margin was included in the activation area on both the T1C 
and T2 saliency maps. The variable importance of the nu-
meric features and their different distributions according 
to IDH status are shown in eFigures 4 and 5. Among the 20 
numeric features, age, frontal lobe location, tumor sphe-
ricity, parietal lobe location, and thalamus location were 
the most important features.
Discussion
We included a total of 1166 patients with gliomas and de-
veloped an automated hybrid model to predict IDH status. 
Our model incorporated information from 2D tumor 
signal intensity, 3D tumor shape and location, and age 
into one CNN along with CNN-based automated tumor 
segmentation and a fully automated pipeline without 
any operator-dependent processes. After developing the 
model based on one institutional dataset, our automated 
hybrid model allowed for IDH status prediction across dif-
ferent cohorts, MR scanners, and imaging protocols, with 
AUROCs ranging from 0.86 to 0.96.
An IDH gene mutation confers a better prognosis and 
treatment response of gliomas, independent of the histo-
logic grade,5,7,24 which led to the integration of IDH status 
for glioma classification in the 2016 update to the WHO 
classification of tumors of the central nervous system.8 
Recent studies have shown that gross total resection 
is more beneficial for IDH-mutant astrocytomas than 
gliomas with other molecular subtypes.9 Although max-
imum tumor resection is the standard treatment regard-
less of IDH status, preoperative prediction of IDH status 
may potentially help in planning for treatments including 
surgery. This led to the investigation of radiological find-
ings to predict IDH status.25,26 However, such visually as-
sessed qualitative radiological findings are predisposed 
to interobserver variability and are only able to provide 
information that is perceivable by visual assessment by 
humans; a previous study conducted a visual assessment 
according to the Visually Accessible Rembrandt Images 
(VASARI) annotations and texture analyses on MR images 
  
Table 1 Patient characteristics
Severance Set (n 
= 856)










Age 52.9 ± 15.4 50.9 ± 15.5 0.194 52.7 ± 14.9 0.818
Sex   0.721  0.305
 Male 492 (57.5) 64 (59.8) 108 (53.2)
 Female 364 (42.5) 43 (40.2) 95 (46.8)
IDH status   >0.999  <0.001
 Wildtype 617 (72.1) 77 (72.0) 119 (58.6)
 Mutation 239 (27.9) 30 (28.0) 84 (41.4)
WHO grade   0.005b  0.054b
 II 175 (20.5) 14 (13.1) 48 (23.7)
  IDH wildtype a 37 (21.1) 5 (35.7) 3 (6.2)
   IDH mutation + 1p/19 non-codeletion 80 (45.7) 1 (7.1) 28 (58.3)
  IDH mutation + 1p/19 codeletion 58 (33.2) 8 (57.2) 17 (35.5)
 III 169 (19.7) 35 (32.7) 52 (25.6)
  IDH wildtype 89 (52.7) 15 (42.9) 17 (32.7)
   IDH mutation + 1p/19 non-codeletion 32 (18.9) 12 (34.3) 24 (46.2)
  IDH mutation + 1p/19 codeletion 48 (28.4) 8 (22.8) 11 (21.1)
 IV 512 (59.8) 58 (54.2) 103 (50.7)
  IDH wildtype 491 (95.9) 57 (98.3) 99 (96.1)
   IDH mutation + 1p/19 non-codeletion 16 (3.1) 1 (1.7) 3 (2.9)
  IDH mutation + 1p/19 codeletion 4 (0.8) 0 (0.0) 1 (1.0)
   IDH mutation + 1p/19q status not 
specified
1 (0.2) 0 (0.0) 0 (0.0)
a Number in parentheses represents the proportion of each molecular subgroup within a specific WHO grade.
bP-value from the chi-square test to compare WHO grade constituents between the two cohorts.
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of lower grade gliomas and reported that the diagnostic 
performance of qualitative VASARI features (AUROC 
mean, 0.73 ± 0.02) was lower than that of quantitative tex-
ture analysis (AUROC mean, 0.86 ± 0.01).26
CNNs and radiomics analysis are representative quan-
titative methods for image analysis and are capable of 
extracting high-dimensional and abstract numeric in-
formation beyond what is perceivable via the visual as-
sessment of a given image. Although CNNs and radiomics 
analysis have shown excellent performance for the pre-
diction of IDH status,10–13 both CNN- and radiomics-based 
classifiers have major obstacles when it comes to clinical 
implementation. First, robust tumor segmentation is a 
major challenge for both CNN-based and radiomics clas-
sifiers. Although semi-automatic segmentation has shown 
greater reproducibility than manual segmentation,27 auto-
matic segmentation is still mandatory to achieve the ideal 
reproducibility. Second, for radiomic features, a major 
cause of limited reproducibility is the lack of a standard 
method for the computation of intensity features (ie, first 
order and texture features), in terms of the ranges of inten-
sity and the number of bins to discretize intensities.28–30 In 
contrast to intensity features, shape and loci features are 
independent from parameters used for intensity feature 
computation; thus, shape and loci features can be stable 
if robust tumor segmentation can be achieved. Third, al-
though CNNs eliminate the steps of feature computation 
and selection by using convolutions to capture the key 
features directly from the images,31 signal intensity–based 
CNNs are not able to directly capture the 3D shape and lo-
cation of tumors that are reported to be distinct depending 
on IDH status.26,32–34
A few studies have applied CNNs for IDH status pre-
diction.10–12 One study with a total of 259 patients from a 
TCIA set developed a CNN model that used 2D image in-
puts selected using a pretrained algorithm for tumor seg-
mentation.10 Another study with 214 patients from a TCIA 
set developed a fully automated network that performs 
  
Table 2 Diagnostic performance of the hybrid model for the prediction of IDH status
Dataset Accuracy AUROC (95% CI) AUPRC (95% CI)
Per slice
 Internal test set 90.50% 0.96 0.95 0.97 0.88 0.82 0.93
 SNUH set 84.90% 0.93 0.9 0.95 0.81 0.74 0.87
 TCIA set 77.10% 0.84 0.81 0.86 0.79 0.74 0.83
Per patienta
 Internal test set 93.80% 0.96 0.93 0.99 0.88 0.72 0.98
 SNUH set 87.90% 0.94 0.89 0.97 0.82 0.65 0.94
 TCIA set 78.80% 0.86 0.8 0.91 0.81 0.71 0.88
AUROC, area under the receiver operating characteristics curve; AUPRC, area under the precision-recall curve.
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Fig. 3 Performance of the hybrid model in the prediction of IDH status. ROC, receiver operating characteristic; PR, precision-recall.
  








tumor segmentation and IDH status prediction simulta-
neously, based on whole brain 3D T2 images.12 However, 
these 2 studies performed cross-validation only to test 
model generalizability without performing external 
testing on a separate dataset.12 Another study enrolled 
a total of 496 multi-institutional patients from 3 different 
datasets to develop a CNN model with 2D image inputs, 
and it is the only study that conducted external testing 
for model generalizability, to the best of our knowledge.11 
Nonetheless, the authors of this study used manual 
tumor segmentation to select the tumor slice for network 
input and did not confirm the improved diagnostic per-
formance of the CNN-based model compared with that 
of age alone; the accuracies in the independent external 
testing ranged 67.1–79.0%, 77.5–84.5%, and 77.7–84.1% for 
prediction by the CNN model only, CNN model combined 
with age, and age alone, respectively.11 To the best of our 
knowledge, a fully automated model with its generaliz-
ability tested on multiple tests with a varying degree of 
similarity to the development set has not been well es-
tablished. Given that not many institutions can be suffi-
ciently equipped with a large patient cohort and technical 
infrastructure that are required for deep learning model 
development, importing the externally trained model 
from a large institution may be a more viable option than 
participating in multi-institutional model development 
from the beginning. Hence, the practical model should 
be generalizable across institutions without being trained 
on samples from those institutions and be reproducible 
via automation. In this study, we attempted to simulate 
the feasible clinical scenario that a fully automated model 
can be developed at a large institution and applied to 
datasets from various institutions.
Model 2 of our hybrid model is different from the pre-
viously reported image-based CNNs10–12 based on the 
fact that 3D tumor shape, loci, and age were integrated 
into one CNN that yielded constantly better model perfor-
mance across datasets than the image only–based CNN. 
The analysis results for model explanation implicate that 
the relevant features for our model prediction are in line 
with those in previous reports. The average age of pa-
tients with IDH-mutant gliomas is several years lower than 
that of patients with IDH wildtype gliomas.5,26,35 IDH mu-
tant gliomas occupy the frontal lobe,34 whereas their IDH 
wildtype counterparts frequently occupy the parietal lobe 
with little frontal lobe involvement.32 IDH wildtype gliomas 
have a higher proportion of enhancement and more ir-
regular tumor boundaries than IDH mutant gliomas.26,33 
Apparent diffusion coefficient as a tumor cellularity index 
was reported to be distinct in terms of IDH status, and 
T2-weighted signal intensity was reported to be related to 
tumor cellularity.36–38
Our results imply that our automated hybrid model can be 
generalized across different MRI scanners, image protocols, 
and cohorts, and it consistently yielded better performance 
than the use of age alone. Nevertheless, it is noteworthy 
that our hybrid model performance varied depending on 
test sets; it was highest in the internal test set, followed by 
the SNUH set and the set from TCIA. Regarding the most 
commonly used imaging parameters, the SNUH set used 
the same 3T magnetic strength and image spatial resolu-
tions that were similar or higher compared with those of the 
Severance set. Contrarily, in the set from TCIA, the magnetic 
strength was 1.5 T, and some image spatial resolutions were 
lower than that of the Severance set, including the slice thick-
ness of T1C that was used as a registration template in im-
aging processing. Thus, the SNUH set represents a dataset 
that is similar to the development set regarding imaging pro-
tocol, IDH mutation proportion, and patient ethnicity (homo-
geneously Korean), whereas the set from TCIA represents an 
extremely heterogeneous dataset that consists of patients of 
multiple ethnicities from multiple institutions with different 
imaging protocols and proportions of IDH mutation com-
pared with the development set. Thus, our results imply that 
the degree of similarity between the development and test 
sets, regarding cohorts and imaging protocols, should be 
  
Table 3 Diagnostic performance of the conventional ResNet, shape/loci radiomic classifier, and age in the prediction of the IDH status
  Dataset Accuracy AUROC (95% CI) AUPRC (95% CI)
Conventional ResNet (per slice) Internal test set 88.70% 0.94 0.92 0.96 0.86 0.8 0.91
SNUH set 81.50% 0.9 0.87 0.92 0.79 0.73 0.85
TCIA set 74.40% 0.79 0.77 0.82 0.72 0.68 0.77
Conventional ResNet (per patient)a Internal test set 92.20% 0.95 0.9 0.98 0.87 0.72 0.97
SNUH set 84.10% 0.91 0.84 0.96 0.81 0.67 0.91
TCIA set 73.50% 0.81 0.74 0.87 0.74 0.63 0.83
Shape/loci radiomics classifier Internal test set 85.30% 0.9 0.83 0.96 0.85 0.74 0.93
SNUH set 79.40% 0.87 0.8 0.93 0.65 0.48 0.85
TCIA set 75.40% 0.84 0.78 0.9 0.77 0.67 0.86
Age Internal test set 72.10% 0.74 0.63 0.84 0.44 0.32 0.59
SNUH set 74.80% 0.81 0.71 0.89 0.51 0.36 0.72
TCIA set 68.50% 0.77 0.7 0.84 0.68 0.57 0.8
AUROC, area under the receiver operating characteristics curve; AUPRC, area under the precision-recall curve.
aSince each patient yielded 5 tumor slices, the diagnostic accuracy per patient was calculated from the mean value of the 5 predicted probabilities 
per patient.
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considered for excellent model performance. Given the good 
model performance in the SNUH set with a difference in 
scanners, our results also imply that if cohort characteristics 
are similar, the scanner-related difference can be substan-
tially overcome by the standardization of image protocols 
across institutions to enhance model generalizability.39
This study has 3 major limitations that merit discus-
sion. First, advanced MRI techniques such as perfusion 
and diffusion weighted imaging were not considered; 
however, our goal was to develop a feasible model 
based on conventional MR images that are widely avail-
able, and using advanced MRI may limit model feasi-
bility. Second, only whole tumor segmentation was used 
to extract shape and loci features, without separate con-
sideration for contrast enhancing tumors and necrosis. 
However, multiple segmentations from one tumor may 
yield redundant tumor shape and loci information that 
do not further enhance the performance of the model. 
Third, although Model 2 incorporated the tumor image, 
shape and loci, and age into one CNN, our model is not 
an end-to-end model; Model 1 for tumor segmenta-
tion and Model 2 for IDH status prediction were sepa-
rately trained and combined afterward. However, image 
preprocessing, Models 1–2, and the pipeline in between 
are completely based on open-source modules that can 
be integrated into a Python-based pipeline, and a test 
sample can be automatically run through each of the 
steps of our model. Thus, our approach to combine the 
2 models is unlikely to be a barrier to clinical feasibility 
and convenience. Moreover, by separately developing 
Models 1–2, each model may have the flexibility to be 
used as an independent building block in the partial ab-
sence of the required MRI sequences or for other appli-
cations in neuro-oncology.
In conclusion, we developed a model from deep 
learning and radiomics that can reliably predict the IDH 
status of gliomas using a fully automated process based 
on conventional MR imaging. Our model has the poten-
tial to be used more widely as a practical tool with high 
reproducibility and generalizability for the noninvasive 
characterization of gliomas to support individualized 
treatment planning.
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Supplementary data are available at Neuro-Oncology 
online.
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